Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, July 22, 2020 (GLOBE NEWSWIRE) -- Caldas Gold Corp. (“Caldas Gold” or the “Company”)...
-
VANCOUVER, British Columbia, July 22, 2020 (GLOBE NEWSWIRE) -- Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV: AME) is pleased to announce a non-brokered private...
-
Total Purchase Consideration of $675 Million Commences Voluntary Chapter 11 Proceedings for U.S. Entities to Implement Sale with New Liquidity of $80 Million in Debtor-in-Possession Financing ...
-
SHANGHAI, China, July 22, 2020 (GLOBE NEWSWIRE) -- Q&K International Group Limited (“Q&K” or the “Company”) (NASDAQ: QK) announced today that one of its subsidiaries has entered into...
-
GOLDEN, Colo., July 21, 2020 (GLOBE NEWSWIRE) -- Golden Minerals Company (NYSE American and TSX: AUMN) (“Golden Minerals”, “Golden” or “the Company”) announced today that, due to demand, the...
-
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering of...
-
Front end engineering design work will commence in August 2020. Spanish Export Credit Agency (CESCE) is expected to finance up to 85% of the contract value. VANCOUVER, British Columbia, July 21,...
-
BOSTON, July 21, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the...
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQB: RVLGF) (“Revival...
-
New York, NY, July 21, 2020 (GLOBE NEWSWIRE) -- Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosis ...